These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

550 related items for PubMed ID: 29704019

  • 1. Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
    Coltoff A, Houldsworth J, Keyzner A, Renteria AS, Mascarenhas J.
    Ann Hematol; 2018 Jul; 97(7):1155-1167. PubMed ID: 29704019
    [Abstract] [Full Text] [Related]

  • 2. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.
    Yin JA, O'Brien MA, Hills RK, Daly SB, Wheatley K, Burnett AK.
    Blood; 2012 Oct 04; 120(14):2826-35. PubMed ID: 22875911
    [Abstract] [Full Text] [Related]

  • 3. High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML).
    Wang L, Gao L, Xu S, Gong S, Liu M, Qiu H, Xu X, Ni X, Chen L, Lu S, Chen J, Song X, Zhang W, Yang J, Hu X, Wang J.
    Ann Hematol; 2014 Oct 04; 93(10):1685-94. PubMed ID: 24844781
    [Abstract] [Full Text] [Related]

  • 4. Optimized clinical application of minimal residual disease in acute myeloid leukemia with RUNX1-RUNX1T1.
    Wei H, Liu X, Wang Y, Lin D, Zhou C, Liu B, Qiu S, Gu R, Li Y, Wei S, Gong B, Liu K, Gong X, Liu Y, Zhang G, Fang Q, Zhang J, Jin J, Ma Y, Mi Y, Wang J.
    Exp Hematol; 2021 Apr 04; 96():63-72.e3. PubMed ID: 33524443
    [Abstract] [Full Text] [Related]

  • 5. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.
    Yalniz FF, Patel KP, Bashir Q, Marin D, Ahmed S, Alousi AM, Chen J, Ciurea SO, Rezvani K, Popat UR, Shpall EJ, Champlin RE, Oran B.
    Cancer; 2020 May 15; 126(10):2183-2192. PubMed ID: 32101640
    [Abstract] [Full Text] [Related]

  • 6. Minimal residual disease in acute myelogenous leukemia with PML/RAR alpha or AML1/ETO mRNA and phenotypic analysis of possible T and natural killer cells in bone marrow.
    Inokuchi K, Iwakiri R, Futaki M, Hanawa H, Tanosaki S, Nomura T, Dan K.
    Leuk Lymphoma; 1998 May 15; 29(5-6):553-61. PubMed ID: 9643569
    [Abstract] [Full Text] [Related]

  • 7. The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.
    Scholl C, Schlenk RF, Eiwen K, Döhner H, Fröhling S, Döhner K, AML Study Group.
    Haematologica; 2005 Dec 15; 90(12):1626-34. PubMed ID: 16330435
    [Abstract] [Full Text] [Related]

  • 8. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.
    Chen X, Xie H, Wood BL, Walter RB, Pagel JM, Becker PS, Sandhu VK, Abkowitz JL, Appelbaum FR, Estey EH.
    J Clin Oncol; 2015 Apr 10; 33(11):1258-64. PubMed ID: 25732155
    [Abstract] [Full Text] [Related]

  • 9. Current strategies for detection and approach to measurable residual disease in acute myeloid leukemia.
    Palmieri R, Buccisano F, Maurillo L, Del Principe MI, Paterno G, Venditti A, Martinelli G, Cerchione C.
    Minerva Med; 2020 Oct 10; 111(5):386-394. PubMed ID: 32955825
    [Abstract] [Full Text] [Related]

  • 10. Clinical significance of minimal residual disease in patients with t(8;21) acute myeloid leukemia in Japan.
    Narimatsu H, Iino M, Ichihashi T, Yokozawa T, Hayakawa M, Kiyoi H, Takeo T, Sawamoto A, Iida H, Tsuzuki M, Yanada M, Naoe T, Suzuki R, Sugiura I.
    Int J Hematol; 2008 Sep 10; 88(2):154-158. PubMed ID: 18553224
    [Abstract] [Full Text] [Related]

  • 11. Monitoring the AML1/ETO fusion transcript to predict outcome in childhood acute myeloid leukemia.
    Zhang L, Cao Z, Ruan M, Zeng Q, Zhao L, Li Q, Zou Y, Wang J, Zhu X.
    Pediatr Blood Cancer; 2014 Oct 10; 61(10):1761-6. PubMed ID: 24920269
    [Abstract] [Full Text] [Related]

  • 12. Competitive CBFbeta/MYH11 reverse-transcriptase polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion(16): a pilot study.
    Laczika K, Novak M, Hilgarth B, Mitterbauer M, Mitterbauer G, Scheidel-Petrovic A, Scholten C, Thalhammer-Scherrer R, Brugger S, Keil F, Schwarzinger I, Haas OA, Lechner K, Jaeger U.
    J Clin Oncol; 1998 Apr 10; 16(4):1519-25. PubMed ID: 9552061
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia.
    Kim T, Moon JH, Ahn JS, Ahn SY, Jung SH, Yang DH, Lee JJ, Shin MG, Choi SH, Lee JY, Tyndel MS, Lee HY, Kim KH, Cai Y, Lee YJ, Sohn SK, Min YH, Cheong JW, Kim HJ, Zhang Z, Kim DDH.
    Sci Rep; 2020 Nov 18; 10(1):20119. PubMed ID: 33208771
    [Abstract] [Full Text] [Related]

  • 15. Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group.
    Rücker FG, Agrawal M, Corbacioglu A, Weber D, Kapp-Schwoerer S, Gaidzik VI, Jahn N, Schroeder T, Wattad M, Lübbert M, Koller E, Kindler T, Götze K, Ringhoffer M, Westermann J, Fiedler W, Horst HA, Greil R, Schroers R, Mayer K, Heinicke T, Krauter J, Schlenk RF, Thol F, Heuser M, Ganser A, Bullinger L, Paschka P, Döhner H, Döhner K.
    Blood; 2019 Nov 07; 134(19):1608-1618. PubMed ID: 31554635
    [Abstract] [Full Text] [Related]

  • 16. Peripheral blood molecular measurable residual disease is sufficient to identify patients with acute myeloid leukaemia with imminent clinical relapse.
    Skou AS, Juul-Dam KL, Ommen HB, Hasle H.
    Br J Haematol; 2021 Nov 07; 195(3):310-327. PubMed ID: 33851435
    [Abstract] [Full Text] [Related]

  • 17. Clinical significance of minimal residual disease in childhood acute myeloid leukemia.
    Miyamura T, Sakata N, Okamura T, Yasui M, Inoue M, Yagi K, Sako M, Komada Y, Matsuyama T, Oda M, Park YD, Kawa K.
    Int J Hematol; 2004 Apr 07; 79(3):243-9. PubMed ID: 15168592
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives.
    Forghieri F, Comoli P, Marasca R, Potenza L, Luppi M.
    Int J Mol Sci; 2018 Nov 06; 19(11):. PubMed ID: 30404199
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.